The global multiple myeloma market was valued at approximately USD 27.75 billion in 2024 and is expected to grow to nearly USD 49.89 billion by 2034, expanding at a CAGR of 6.04%. This growth is driven by the rising prevalence of multiple myeloma and increased demand for treatments including medications, immunotherapy, stem cell transplants, and radiation therapy. North America currently leads the market, while Asia-Pacific shows promising growth. Immunomodulators dominate the drug class segment, with proteasome inhibitors projected to grow substantially. Hospital pharmacies currently serve as the primary distribution channel, but retail pharmacies are rapidly gaining traction.
Download this Free Sample Now and Get the Complete Report and Insights of this Market Easily @ https://www.towardshealthcare.com/download-sample/5489
Top 10 Leading Companies in Multiple Myeloma Market
1. Bristol-Myers Squibb (BMS)
Strengths: Strong oncology portfolio, innovative CAR-T therapies, extensive R&D investment.
Key Products:
• Revlimid (Lenalidomide) – an immunomodulator widely used in multiple myeloma.
• Empliciti (Elotuzumab) – monoclonal antibody targeting SLAMF7.
• Abecma (Idecabtagene vicleucel) – first FDA-approved CAR-T cell therapy for multiple myeloma.
2. Amgen Inc.
Strengths: Leading biopharmaceutical company with strong biologics pipeline, robust global presence.
Key Products:
• Kyprolis (Carfilzomib) – a proteasome inhibitor used in relapsed multiple myeloma.
• Blincyto – though mainly for leukemia, reflects Amgen’s immunotherapy strength.
3. Johnson & Johnson (Janssen Pharmaceuticals)
Strengths: Extensive oncology portfolio, strong marketing and distribution network, strong R&D pipeline.
Key Products:
• Darzalex (Daratumumab) – CD38-targeting monoclonal antibody for multiple myeloma.
• Imnovid (Pomalidomide) – immunomodulatory drug.
4. Takeda Pharmaceutical Company
Strengths: Focus on hematology and oncology, strong pipeline and collaborations, significant global footprint.
Key Products:
• Velcade (Bortezomib) – pioneering proteasome inhibitor in multiple myeloma treatment.
• Ninlaro (Ixazomib) – oral proteasome inhibitor.
5. Novartis AG
Strengths: Broad oncology portfolio, innovative drug development, global reach.
Key Products:
• Pomalyst (Pomalidomide) – immunomodulatory drug.
• Kymriah – CAR-T therapy platform (primarily for other cancers but reflects tech capability).
6. Sanofi S.A.
Strengths: Strong research and development, diverse pharmaceutical portfolio, strategic acquisitions.
Key Products:
•Sarclisa (Isatuximab) – monoclonal antibody targeting CD38.
• Myozyme – showcases Sanofi’s biologics expertise.
7. Celgene (now part of Bristol-Myers Squibb)
Strengths: Former leader in immunomodulators and targeted therapies, now integrated with BMS’s oncology arm.
Key Products:
• Revlimid (Lenalidomide) – flagship drug for multiple myeloma treatment.
8. GSK (GlaxoSmithKline)
Strengths: Strong in immunotherapies and monoclonal antibodies, extensive global distribution.
Key Products:
• Blincyto (Blinatumomab) – bispecific antibody (more leukemia-focused but indicates immune therapy strength).
9. Regeneron Pharmaceuticals
Strengths: Cutting-edge monoclonal antibodies and immunotherapy, robust R&D in oncology.
Key Products:
• Libtayo (Cemiplimab) – PD-1 inhibitor with potential applications.
• Pipeline focused on immuno-oncology, including multiple myeloma.
10. Karyopharm Therapeutics
Strengths: Specialized focus on cancer therapies, innovative drug candidates, growing presence in multiple myeloma.
Key Products:
• XPOVIO (Selinexor) – first-in-class nuclear export inhibitor approved for multiple myeloma.
Fill the given form below and get the complete report immediately
Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/price/5489
Access our exclusive, data-rich dashboard dedicated to the healthcare market – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
About the Author
